Nuvigil — Competitive Intelligence Brief

Nuvigil (ARMODAFINIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: armodafinil. Area: Rare Disease.

marketed armodafinil D(2) dopamine receptor Rare Disease Small molecule

Target snapshot

Nuvigil (ARMODAFINIL) — Nuvo Pharms. Nuvigil works by selectively targeting the D(2) dopamine receptor to increase wakefulness and alertness.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nuvigil TARGET	ARMODAFINIL	Nuvo Pharms	marketed	armodafinil	D(2) dopamine receptor	2007-01-01
Aripiprazole Augmentation	Aripiprazole Augmentation	Centre for Addiction and Mental Health	marketed	Atypical antipsychotic / dopamine partial agonist	D2 dopamine receptor, 5-HT1A serotonin receptor
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Adjunctive asenapine	Adjunctive asenapine	Lori Davis, MD	marketed	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor
Pramipexole (Mirapex)	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor
LYBALVI	LYBALVI	Alkermes, Inc.	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor
Continuous Subcutaneous Lisuride Infusion	Continuous Subcutaneous Lisuride Infusion	Axxonis Pharma AG	phase 3	Dopamine agonist	D1 and D2 dopamine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (armodafinil class)

1. Nuvo Pharms · 1 drug in this class